WO2002012346A3 - A new slit-like protein obtained from a cdna library from hs-5 stromal cell line - Google Patents

A new slit-like protein obtained from a cdna library from hs-5 stromal cell line Download PDF

Info

Publication number
WO2002012346A3
WO2002012346A3 PCT/US2001/025242 US0125242W WO0212346A3 WO 2002012346 A3 WO2002012346 A3 WO 2002012346A3 US 0125242 W US0125242 W US 0125242W WO 0212346 A3 WO0212346 A3 WO 0212346A3
Authority
WO
WIPO (PCT)
Prior art keywords
slit
cell line
cdna library
stromal cell
protein
Prior art date
Application number
PCT/US2001/025242
Other languages
French (fr)
Other versions
WO2002012346A2 (en
WO2002012346A8 (en
Inventor
Porul D Doshi
Martin F Meier
Cynthia L Woods
Original Assignee
Pharmacia Corp
Porul D Doshi
Martin F Meier
Cynthia L Woods
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Porul D Doshi, Martin F Meier, Cynthia L Woods filed Critical Pharmacia Corp
Priority to CA002423519A priority Critical patent/CA2423519A1/en
Priority to AU2001286446A priority patent/AU2001286446A1/en
Priority to JP2002518317A priority patent/JP2004523210A/en
Priority to EP01965890A priority patent/EP1307559A2/en
Publication of WO2002012346A2 publication Critical patent/WO2002012346A2/en
Publication of WO2002012346A8 publication Critical patent/WO2002012346A8/en
Publication of WO2002012346A3 publication Critical patent/WO2002012346A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)

Abstract

The present invention relates to a new Slit-like protein obtained from a cDNA library from HS-5 stromal cell line, nucleic acid molecules that encode the Slit-like protein or a fragment thereof and nucleic acid molecules that are useful as probes or primers for detecting or amplifying the Slit-like protein, respectively. The invention further relates to uses of the Slit-like protein. The invention also relates to applications of the factor or fragment such as forming antibodies capable of binding the factor or fragments thereof.
PCT/US2001/025242 2000-08-10 2001-08-10 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line WO2002012346A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002423519A CA2423519A1 (en) 2000-08-10 2001-08-10 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
AU2001286446A AU2001286446A1 (en) 2000-08-10 2001-08-10 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
JP2002518317A JP2004523210A (en) 2000-08-10 2001-08-10 Novel Slit-like protein obtained from cDNA library from HS-5 stromal cell line
EP01965890A EP1307559A2 (en) 2000-08-10 2001-08-10 Slit-like protein obtained from a cdna library from hs-5 stromal cell line

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63616900A 2000-08-10 2000-08-10
US09/636,169 2000-08-10

Publications (3)

Publication Number Publication Date
WO2002012346A2 WO2002012346A2 (en) 2002-02-14
WO2002012346A8 WO2002012346A8 (en) 2002-07-04
WO2002012346A3 true WO2002012346A3 (en) 2002-09-12

Family

ID=24550722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025242 WO2002012346A2 (en) 2000-08-10 2001-08-10 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line

Country Status (5)

Country Link
EP (1) EP1307559A2 (en)
JP (1) JP2004523210A (en)
AU (1) AU2001286446A1 (en)
CA (1) CA2423519A1 (en)
WO (1) WO2002012346A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010586A1 (en) * 2005-07-14 2007-01-25 The University Of Tokyo Hematopoietic stem cell identifier
EP2212344B1 (en) * 2007-09-14 2014-03-26 Formycon AG Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035170A2 (en) * 1998-01-05 1999-07-15 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2000042170A1 (en) * 1998-04-21 2000-07-20 Millennium Pharmaceuticals, Inc. Novel lrsg protein and nucleic acid molecules and uses therefor
WO2000061623A1 (en) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 62 human secreted proteins
WO2001046418A1 (en) * 1999-12-21 2001-06-28 Zymogenetics, Inc. Human slit polypeptide zslit3

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035170A2 (en) * 1998-01-05 1999-07-15 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2000042170A1 (en) * 1998-04-21 2000-07-20 Millennium Pharmaceuticals, Inc. Novel lrsg protein and nucleic acid molecules and uses therefor
WO2000061623A1 (en) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 62 human secreted proteins
WO2001046418A1 (en) * 1999-12-21 2001-06-28 Zymogenetics, Inc. Human slit polypeptide zslit3

Also Published As

Publication number Publication date
JP2004523210A (en) 2004-08-05
EP1307559A2 (en) 2003-05-07
AU2001286446A1 (en) 2002-02-18
WO2002012346A2 (en) 2002-02-14
CA2423519A1 (en) 2002-02-14
WO2002012346A8 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
WO2002004523A3 (en) Artificial antibody polypeptides
WO2004035170A3 (en) Composition for separating molecules
WO2004058990A3 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
WO2004029220A3 (en) Synthetic genes
WO2002014485A3 (en) Kallikrein gene
WO2005005462A3 (en) Blys antagonists and uses thereof
WO2005111241A8 (en) Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
ATE419629T1 (en) POROUS FERRO- OR FERRI-MAGNETIC GLASS PARTICLES FOR MOLECULE SEPARATION
WO2002055562A3 (en) Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
WO2001036641A3 (en) DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
AU2001241433A1 (en) Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties
WO2002024912A3 (en) Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
WO2004007664A3 (en) Nucleic acid vectors
WO2004106367A3 (en) Enterococcus antigens
WO2004077038A3 (en) Stationary phase for use in capillary electrophoresis, capillary electrochromatography, microfluidics, and related methods
WO2002049625A3 (en) Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
WO2005063813A3 (en) Process for the production of tumor necrosis factor-binding proteins
WO2002012346A3 (en) A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
WO2006135738A3 (en) Devices from prion-like proteins
WO2003018631A3 (en) Nogo receptor homologues and their use
WO2002061046A3 (en) Novel nucleic acid and polypeptide molecules
WO2002012335A3 (en) A NEW EGF MOTIF REPEAT PROTEIN OBTAINED FROM A cDNA LIBRARY FROM HS-5 STROMAL CELL LINE
WO2001066752A3 (en) Reproduction-specific genes
WO2004090103A3 (en) Identification of novel nogo-receptors and methods related thereto
WO2002014491A3 (en) A hematopoietic growth factor-like protein obtained from a cdnalibrary from hs-5 stromal cell line

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 2423519

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001965890

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002518317

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001965890

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001965890

Country of ref document: EP